Physician profile
Javier E Rios
NPI 1114504693
$1,641.73
in general payments reported to CMS, 2019-2025
6 companies · $929 in 2025
The $929 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $210 · 2023: $255 · 2024: $247 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $372.62 | 2024-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $314.04 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $301.64 | 2022-2023 | Arexvy |
| Amgen INC. | $286.39 | 2023-2025 | Uplizna, Repatha |
| Astrazeneca Pharmaceuticals LP | $243.70 | 2022-2025 | Airsupra |
| La Jolla Pharmaceutical Company | $123.34 | 2023 | Xerava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.